Colivelin Evidence Guide
Evidence for Colivelin is too preliminary to support a research protocol with confidence. All data comes from mouse models of Alzheimer's disease, with no human pharmacokinetic data, no safety studies, and no clinical trials. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has far more clinical evidence as a starting point for neuroprotective research.
Our Take
Evidence for Colivelin is too preliminary to support a research protocol with confidence. All data comes from mouse models of Alzheimer's disease, with no human pharmacokinetic data, no safety studies, and no clinical trials. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has far more clinical evidence as a starting point for neuroprotective research.
- Evidence context
- CNTF/humanin hybrid neuroprotection mechanistic research (mouse only)
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established human protocol
Benefits and Evidence
- Neuroprotection Against Amyloid-Beta: Level D, mostly non-human evidence - Colivelin protects neurons from amyloid-beta 1-42 and amyloid-beta 25-35 toxicity at femtomolar to picomolar concentrations in culture, far more potent than either component peptide alone.
- Cognitive Rescue in AD Models: Level D, mostly non-human evidence - Intracerebroventricular administration of Colivelin rescued spatial memory deficits in multiple AD mouse models (3xTg, amyloid-beta-injected), restoring Morris water maze performance to near-normal levels.
- Anti-Apoptotic Activity: Level D, mostly non-human evidence - Colivelin inhibits Bax-mediated mitochondrial apoptosis, reduces caspase-3 activation, and maintains mitochondrial membrane potential under neurotoxic conditions.
Side Effects and Warnings
- No adverse effects reported in published animal studies
- Unknown human safety profile
- Potential for unexpected effects from dual-pathway activation
- All data is preclinical - no human studies exist
- Brain delivery remains a major challenge for systemic administration
- Dual-pathway activation (MAPK + STAT3) could have complex effects in chronic administration
- No established clinical product or routine therapeutic access
Research Dosage References
- <strong>Intracerebroventricular (animal studies)</strong> - 1-10 pmol - Single or repeated doses - ICV administration used in mouse studies. Active at extremely low (femtomolar to picomolar) concentrations. Systemic delivery and human dosing not established.
Mechanism of Action
Colivelin activates two parallel neuroprotective cascades: (1) The ADNF-9 moiety binds to heat shock protein 60 (HSP60), which activates the MAPK/ERK1/2 pathway, promoting neuronal survival gene expression and synaptic protein synthesis; (2) The AGA-HNG17 (Humanin) moiety binds to the CNTF receptor complex (CNTFR/WSX-1/gp130 trimer), activating JAK2/STAT3 signaling and suppressing Bax translocation to mitochondria, thereby preventing cytochrome c release and caspase activation. The dual mechanism provides synergistic protection against amyloid-beta toxicity, oxidative stress, and excitotoxicity.
Legal Status
Research compound only; not approved for any clinical use.
Primary Sources
- Colivelin: a neuroprotective peptide that combines Humanin and ADNF-9 activities. Molecular Brain Research, 2005.
- Colivelin rescues cognitive deficits in triple transgenic Alzheimer mice. Journal of Neuroscience Research, 2009.
Quick Answers
Where is the strongest evidence for Colivelin?
Evidence for Colivelin is too preliminary to support a research protocol with confidence. All data comes from mouse models of Alzheimer's disease, with no human pharmacokinetic data, no safety studies, and no clinical trials. Of the Cognitive & Nootropic compounds in this library, cerebrolysin has far more clinical evidence as a starting point for neuroprotective research. Evidence context: CNTF/humanin hybrid neuroprotection mechanistic research (mouse only).
What are the main side effects of Colivelin?
Colivelin side effects and warning signals include No adverse effects reported in published animal studies, Unknown human safety profile, Potential for unexpected effects from dual-pathway activation, All data is preclinical - no human studies exist, and Brain delivery remains a major challenge for systemic administration.
What evidence level is Colivelin?
Colivelin is rated Level D; the listed research status is Preclinical.